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INTRODUCTION
Deleterious protein misfolding and aggregation underpin multiple devastating neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease (PD) Brettschneider et al. 2015; Eisele et al. 2015) . In ∼97% of ALS cases and ∼45% of FTD cases, a predominantly nuclear RNA-binding protein with a prion-like domain, TDP-43, mislocalizes to cytoplasmic inclusions and becomes depleted from the nucleus in degenerating neurons (Neumann et al. 2006; King, Gitler and Shorter 2012; Li et al. 2013; Ling, Polymenidou and Cleveland 2013; Guo and Shorter 2017) . However, ALS and FTD can present without TDP-43 pathology (Ling, Polymenidou and Cleveland 2013) . Indeed, in ∼1% of ALS cases and ∼9% of FTD cases, another primarily nuclear RNA-binding protein with a prion-like domain, FUS, exhibits nuclear depletion and cytoplasmic aggregation in afflicted neurons (Kwiatkowski et al. 2009; Vance et al. 2009; March, King and Shorter 2016; Harrison and Shorter 2017) . These TDP-43 and FUS pathologies likely cause a toxic gain-of-function in the cytoplasm and a toxic loss-of-function of these RNA-binding proteins in the nucleus (Harrison and Shorter 2017) . Indeed, TDP-43 and FUS perform important functions in pre-mRNA splicing, transcription, translation, RNA processing, and RNA transport and together regulate the expression of thousands of human genes (Polymenidou et al. 2011; Lagier-Tourenne et al. 2012; Ling, Polymenidou and Cleveland 2013) . Protein disaggregases that liberate and reactivate TDP-43 and FUS trapped in cytoplasmic inclusions and restore functional TDP-43 and FUS to the nucleus could be valuable therapeutics for ALS and FTD (Guo and Shorter 2017; Harrison and Shorter 2017) .
In PD, the small, presynaptic, lipid-binding protein α-synuclein (α-syn) forms toxic oligomers and amyloids, which accumulate in cytoplasmic deposits termed Lewy bodies in degenerating dopaminergic neurons (Auluck, Caraveo and Lindquist 2010; Winner et al. 2011; Snead and Eliezer 2014; Abeliovich and Gitler 2016) . Although the precise function of α-syn is uncertain, it likely plays important roles in synaptic vesicle trafficking (Gitler and Shorter 2007; Snead and Eliezer 2014; Abeliovich and Gitler 2016) . These functions are likely perturbed via sequestration in toxic oligomers and Lewy Bodies. Thus, protein disaggregases that safely disassemble α-syn oligomers and amyloid, and recover functional α-syn could have curative properties in PD and other synucleinopathies (Shorter 2008; Snead and Eliezer 2014; Dehay et al. 2015) .
In search of therapeutic agents, we have endeavored to tailor Hsp104, a hexameric AAA + protein disaggregase found in yeast, to safely disassemble toxic oligomers, aggregates, and amyloids connected to neurodegenerative diseases such as ALS, FTD, and PD (Shorter 2008 (Shorter , 2016 (Shorter , 2017 Shorter 2015, 2017) . Each Hsp104 protomer contains an N-terminal domain, nucleotide-binding domain 1 (NBD1), a middle domain (MD), NBD2, and a short C-terminal domain (Fig. 1A ) (Sweeny and Shorter 2016) . Hsp104 assembles into asymmetric ring-like or lock-washer hexamers (Wendler et al. 2009; Yokom et al. 2016; Gates et al. 2017) , which extract individual polypeptides from aggregated structures via partial or complete translocation across their central channel (Lum et al. 2004; Shorter and Lindquist 2005a; Haslberger et al. 2008; Lum, Niggemann and Glover 2008; Tessarz, Mogk and Bukau 2008; Castellano et al. 2015; Sweeny et al. 2015) . Polypeptide translocation is driven via ratchet-like conformational changes of the hexamer that are coupled to ATP binding and hydrolysis (Yokom et al. 2016; Gates et al. 2017) . Hsp104 disaggregase activity can be boosted by additional molecular chaperones, including Hsp110, Hsp70, Hsp40, Hsp42, and Hsp26 (Glover and Lindquist 1998; Cashikar, Duennwald and Lindquist 2005; Haslbeck et al. 2005; Shorter and Lindquist 2008; Sweeny and Shorter 2008; Shorter 2011; Duennwald, Echeverria and Shorter 2012; Sweeny et al. 2015; Kaimal et al. 2017) . Hsp104 liberates diverse polypeptides trapped in insoluble phases that accumulate after stress in yeast, and thereby confers large selective advantages (Sanchez and Lindquist 1990; Parsell et al. 1991 Parsell et al. , 1994 Sanchez et al. 1992 Sanchez et al. , 1993 Glover and Lindquist 1998; Shorter 2008; Wallace et al. 2015) . Hsp104 also has a powerful amyloid-dissolvase activity (Paushkin et al. 1996; Lindquist 2004, 2006; DeSantis and Shorter 2012b; Klaips et al. 2014; Sweeny et al. 2015; Pei et al. 2017; Zhao et al. 2017) , which enables yeast to utilize and tightly regulate various prions for beneficial purposes (Chernoff et al. 1995; True and Lindquist 2000; True, Berlin and Lindquist 2004; Shorter and Lindquist 2005b; Halfmann, Alberti and Lindquist 2010; Tuite and Serio 2010; Newby and Lindquist 2013; Harvey, Chen and Jarosz 2017; Jarosz and Khurana 2017) .
Importantly, the amyloid-dissolvase activity of Hsp104 can be turned against human neurodegenerative disease proteins. Indeed, Hsp104 dissolves diverse amyloids and toxic preamyloid oligomers formed by many wild-type and diseaselinked mutant proteins connected to human disease, including amyloid-β, tau, α-syn, prion protein, polyglutamine and amylin (Lo Bianco et al. 2008; Liu et al. 2011; Shorter 2011; Duennwald, Echeverria and Shorter 2012) . Moreover, Hsp104 mitigates neurodegeneration in animal models of disease (Satyal et al. 2000; Vacher, Garcia-Oroz and Rubinsztein 2005; Perrin et al. 2007; Lo Bianco et al. 2008; Cushman-Nick, Bonini and Shorter 2013) . Despite these encouraging advances, effective amyloid dissolution can require high Hsp104 concentrations and Hsp104 is ineffective against TDP-43 and FUS (Lo Bianco et al. 2008; Jackrel and Shorter 2014a; Jackrel et al. 2014a) . To circumvent these issues, we have engineered potentiated Hsp104 variants with enhanced disaggregase activity against TDP-43, FUS, and α-syn (Jackrel et al. 2014a Shorter 2014a,b, 2015; Sweeny et al. 2015; Torrente et al. 2016) .
Engineered Hsp104 variants with enhanced disaggregase activity successfully antagonize TDP-43, FUS, and α-syn aggregation and toxicity in yeast under conditions where Hsp104 is ineffective (Jackrel and Shorter 2014a; Jackrel et al. 2014a . This suppression of toxicity is accompanied by relocalization of TDP-43 to the nucleus and relocalization of α-syn to the plasma membrane, indicating that protein functionality is likely restored by Hsp104 variants (Jackrel and Shorter 2014a; Jackrel et al. 2014a) . Potentiated Hsp104 variants also dissolve TDP-43, FUS, and α-syn fibrils more effectively than Hsp104 in vitro (Jackrel and Shorter 2014a; Jackrel et al. 2014a) . Moreover, enhanced Hsp104 variants reverse cytoplasmic aggregation and mislocalization of ALS-linked FUS in mammalian cells (Yasuda et al. 2017) and mitigate dopaminergic neurodegeneration caused by α-syn in a Caenorhabditis elegans model of PD (Jackrel et al. 2014a) . Thus, engineered Hsp104 variants may be effective therapeutic agents to be advanced in preclinical studies.
The majority of potentiating mutations isolated to date reside in the MD of Hsp104 (Jackrel et al. 2014a . The MD is an important autoregulatory domain of Hsp104, which encircles the disaggregase and enables interdomain communication between NBD1 and NBD2 and collaboration with Hsp70 (Cashikar et al. 2002; Shorter 2012a, 2014; Lee et al. 2013; Heuck et al. 2016; Yokom et al. 2016; Gates et al. 2017) . Potentiating mutations have been found in all four helices of the MD . Some of these mutations may alter inter-protomer contacts between MD helix L1 and MD helix L3 or contacts between the MD and NBD1 (Heuck et al. 2016; Gates et al. 2017) . Remarkably, very minor changes in primary sequence can result in enormous changes in disaggregase activity. Indeed, a single missense mutation can potentiate Hsp104 and may be as subtle as removal of a single methyl group (e.g. A503G), removal of a single methylene bridge (e.g. E469D), or addition of a single methylene bridge (e.g. V426L) (Jackrel et al. 2014a Jackrel and Shorter 2015) . The subtle nature of some potentiating mutations suggests that post-translational modifications of Hsp104 at specific positions in the MD or NBD1 might also potentiate activity. Indeed, several serine and threonine residues throughout Hsp104 can be phosphorylated in vivo, including T87 and S155 in the NTD, S206 and S306 in NBD1, T499 and S535 in the MD, and S577, S578, and S768 in NBD2 (Fig. 1A ) (Albuquerque et al. 2008; Holt et al. 2009; Swaney et al. 2013 
MATERIALS AND METHODS

Yeast strains, plasmids and media
Yeast were WT W303a (MATa, 15, 112, or the isogenic strain W303a hsp104 (Jackrel et al. 2014a) . Media was supplemented with 2% glucose, raffinose, or galactose as specified. The yeast strains W303a hsp104 303GAL-α-syn, FUS, and TDP-43 have been previously described (Jackrel and Shorter 2014a; Jackrel et al. 2014a,b) . QuikChange site-directed mutagenesis (Agilent, Santa Clara, CA, USA) was used to create mutations in the pRS416GAL-Hsp104 plasmid and all mutations were confirmed by DNA sequencing.
Yeast transformation and spotting assays
Yeast transformations were performed using standard polyethylene glycol and lithium acetate procedures (Gietz and Schiestl 2007) . For the spotting assays, yeasts were grown to saturation in raffinose supplemented dropout media overnight at 30
• C. The saturated overnight cultures were serially diluted 5-fold, and a 96-bolt replicator tool (frogger) was used to spot the strains in duplicate onto both glucose and galactose dropout plates. These plates were grown at 30
• C and imaged after 72 h to assess suppression of disease-protein toxicity.
Western blotting
Transformed phosphomimetic mutants and controls were grown overnight in raffinose media. The overnight cultures were diluted to an OD of 0.3 (A 600nm = 0.3) and grown in galactosesupplemented media at 30
• C. α-Syn samples were induced for 8 h, while FUS and TDP-43 samples were induced for 5 h. Samples were then normalized to an OD of 0.6. The pelleted cells were resuspended in 0.1 M NaOH for 5 min and then pelleted again and resuspended in 1x SDS sample buffer. The samples were then boiled and separated by SDS-PAGE (4%-20% gradient, Bio-Rad, Hercules, CA, USA), and then transferred to a PVDF membrane (Millipore). The following primary antibodies were used: anti-GFP monoclonal (Roche Applied Science, Penzburg, Germany), anti-FUS polyclonal (Bethyl Laboratories, Montgomery, TX, USA), anti-TDP-43 polyclonal (Proteintech, Rosemont, IL, USA), antiHsp104 polyclonal (Enzo Life Sciences, Farmingdale, NY, USA) and anti-PGK monoclonal (Invitrogen, Carlsbad, CA, USA). Blots were imaged using a LI-COR Odyssey FC Imaging system.
Toxicity assay
Phosphomimetic mutants along with applicable controls were transformed into W303a hsp104 yeast. The strains were grown overnight in raffinose dropout media at 30
• C with shaking. The saturated cultures were spotted in duplicate onto two sets of SDUra and SGal-Ura plates. One set of plates was placed at 37
• C and the other at 30
• C. Both sets of plates were analyzed for toxicity after 72h.
Fluorescence microscopy
Microscopy samples were grown and induced as they were for immunoblotting. For TDP-43 samples, cells were harvested, fixed in 1 mL 70% ethanol, and immediately pelleted. 
Generative REgularized models of proteINs (GREMLIN) coevolution analysis
GREMLIN coevolution analysis was performed using OPENSEQ.org web server supported by David Baker's lab (http://gremlin.bakerlab.org/) (Ovchinnikov, Kamisetty and Baker 2014) . The S. cerevisiae Hsp104 primary sequence was used for the analysis. The Jackhammer method was used to generate the diversity multiple sequence alignment (MSA). An E-value of 1E −10 and interactions of four were chosen to control the MSA generation. Filter MSA parameters were set to remove sequences that did not cover at least 75% of query. After coverage filter, positions in the alignment that have 75% of gaps were removed.
Protein purification and biochemistry assays
Protein purification was performed as described previously (Jackrel et al. 2014a) . ATPase activity and luciferase disaggregation and reactivation assays were performed as described (Jackrel et al. 2014a) .
RESULTS
Hsp104
T499D and Hsp104 S535D suppress α-syn toxicity, aggregation and promote its plasma membrane localization A number of serine and threonine residues in Hsp104 can be phosphorylated in vivo, including T87 and S155 in the NTD, S206 and S306 in NBD1, T499 and S535 in the MD, and S577, S578, and S768 in NBD2 (Fig. 1A) (Albuquerque et al. 2008; Holt et al. 2009; Swaney et al. 2013) . To assess whether serine or threonine phosphorylation at these positions might enhance Hsp104 activity, we introduced single phosphomimetic aspartate or glutamate substitutions at these positions in Hsp104. We then determined whether these phosphomimetic Hsp104 variants could antagonize α-syn toxicity in yeast. Upon expression from the inducible galactose promoter, α-syn accumulates in cytoplasmic aggregates and is toxic to yeast thereby recapitulating the phenotype of degenerating dopaminergic neurons in PD patients (Outeiro and Lindquist 2003) . This yeast model of α-syn aggregation and toxicity has been tremendously valuable in identifying novel genetic and small-molecule suppressors of α-syn toxicity, which have translated to worm, fly, mouse, and patient-derived neuronal models of PD (Cooper et al. 2006; Gitler et al. 2008 Gitler et al. , 2009 Su et al. 2010; Chung et al. 2013; Tardiff and Lindquist 2013; Caraveo et al. 2014 Caraveo et al. , 2017 Jackrel et al. 2014a; Khurana et al. 2017) .
α-Syn overexpression is toxic to yeast (Fig. 1B) and is an established cause of PD (Singleton et al. 2003) . This α-syn toxicity cannot be buffered by wild-type Hsp104 (Fig. 1B) shown). Altogether, we find phosphomimetic mutations at T499 or S535 in the MD potentiate Hsp104 activity, whereas single phosphomimetic mutations at T87 or S155 in the NTD, or S206 or S306 in NBD1, or S577, S578, or S768 in NBD2 do not. Several positions in the MD can be mutated to diverse amino acids and confer potentiated Hsp104 activity (Jackrel et al. 2014a) . For example, A503 in helix L3 of the MD can be mutated to any amino acid, except proline, and enable Hsp104 to strongly suppress α-syn, FUS, and TDP-43 toxicity (Jackrel et al. 2014a) . To confirm that enhanced Hsp104 activity was due to the phosphomimetic mutation at T499 or S535 rather than a general effect of any mutation, we generated the T499A and S535A variants. Unlike Hsp104 T499D or Hsp104 S535D , neither Hsp104 T499A nor Hsp104 S535A rescued α-syn toxicity despite robust expression ( Fig. 1D and E) . Thus, unlike A503, not any mutation at T499 or S535 potentiates Hsp104 activity. Indeed, we also assessed T499I, a mutation that when combined with G217S causes Hsp104 to be toxic (Schirmer et al. 2004) . Hsp104 T499I exhibits mildly reduced ATPase activity in vitro, but confers thermotolerance in vivo (Schirmer et al. 2004) . Like Hsp104 T499A , Hsp104 T499I was unable to rescue α-syn toxicity (data not shown). Moreover, we have previously shown that Hsp104 T499V does not rescue α-syn toxicity (Jackrel et al. 2014a) . Thus, only select missense mutations at the T499 position confer potentiated activity. α-Syn accumulates in cytoplasmic aggregated structures in yeast that are not affected by expression of Hsp104 (Fig. 1F and  G) . Indeed, ∼70% of cells present with cytoplasmic α-syn foci in the vector control or in the presence of Hsp104 (Fig. 1F) . In contrast, the potentiated variant, Hsp104 A503V , antagonizes formation of cytoplasmic α-syn foci and enables α-syn to localize to the plasma membrane in ∼90% of cells ( Fig. 1F and G) . The MD phosphomimetic variants, Hsp104 T499D and Hsp104 S535D , also suppressed the formation of cytoplasmic α-syn aggregates and enabled α-syn localization to the plasma membrane in ∼80% and ∼50% of cells, respectively ( Fig. 1F and G) . Thus, Hsp104 T499D and Hsp104 S535D are not as effective as Hsp104 A503V in suppressing cytoplasmic α-syn aggregation. Regardless, the level of protection against cytoplasmic α-syn aggregation conferred by Hsp104 T499D and Hsp104 S535D is sufficient to potently mitigate α-syn toxicity (Fig. 1B and D) .
T499D and Hsp104 S535D suppress TDP-43 toxicity, aggregation and promote its nuclear localization Next, we assessed the same single phosphomimetic aspartate or glutamate Hsp104 variants against TDP-43 aggregation and toxicity in yeast. TDP-43 is a mostly nuclear protein that shuttles between the nucleus and cytoplasm, but aggregates and mislocalizes to the cytoplasm of degenerating motor neurons in ALS and cortical neurons in FTD (Guo and Shorter 2017) . Overexpression of TDP-43 in yeast replicates these phenotypes of cytoplasmic aggregation and toxicity (Johnson et al. 2008 (Johnson et al. , 2009 ). Indeed, TDP-43 overexpression is connected to FTD (Gitcho et al. 2009 ). This yeast model of TDP-43 aggregation and toxicity has empowered the discovery of key genetic and small-molecule modifiers of TDP-43 toxicity, which have translated to fly, mouse, and neuronal models of ALS/FTD (Elden et al. 2010; Armakola et al. 2012; Tardiff et al. 2012; Kim et al. 2014; Jackrel et al. 2014a; Becker et al. 2017) . Indeed, this yeast model sparked the discovery of intermediate-length, polyglutamine expansions (∼27-33 glutamines) in ataxin 2 as a common risk factor for ALS (Elden et al. 2010; Lee et al. 2011a,b; Yu et al. 2011; Auburger et al. 2017) .
TDP-43 toxicity was not rescued by Hsp104 or by any of the aspartate or glutamate phosphomimetic variants in the NTD, NBD1, or NBD2 ( Fig. 2A) . In contrast, the MD phosphomimetic variants, Hsp104 T499D and Hsp104 S535D , mitigated TDP-43 toxicity ( Fig. 2A) and was not due to gross reductions in TDP-43 expression levels ( Fig. 2A and B) . In contrast, Hsp104 T499A , Hsp104 T499I , Hsp104
T499V
and Hsp104 S535A did not rescue TDP-43 toxicity ( Fig. 2C and D; data not shown) (Jackrel et al. 2014a ). Thus, phosphomimetic mutations at T499 or S535 enhanced Hsp104 activity against TDP-43, whereas alanine, valine or isoleucine substitutions at T499 or alanine substitution at S535 did not. We determined that Hsp104 T499D and Hsp104 S535D also suppressed TDP-43 aggregation and mislocalization ( Fig. 2E and F) . In yeast expressing Hsp104 or the vector control, TDP-43 was found in the nucleus in ∼35% of cells, whereas ∼65% had cytoplasmic TDP-43 aggregates ( Fig. 2E and F 
Hsp104
T499D and Hsp104 S535D suppress FUS toxicity and aggregation
We next assessed phosphomimetic Hsp104 variants against FUS proteotoxicity. FUS overexpression in yeast induces cytoplasmic FUS aggregation and toxicity, thereby mimicking events in degenerating neurons in ALS or FTD with FUS pathology (Ju et al. 2011; Sun et al. 2011; Harrison and Shorter 2017) . Moreover, elevated FUS expression is also connected to neurodegenerative disease (Sabatelli et al. 2013; Dini Modigliani et al. 2014 ). This yeast model of FUS proteinopathies has enabled discovery of several genetic modifiers of FUS toxicity, which have translated to fly, mammalian cell and neuronal models of ALS and FTD (Sun et al. 2011; Daigle et al. 2013; Jackrel et al. 2014a; Barmada et al. 2015; Daigle et al. 2016; Yasuda et al. 2017) .
As with α-syn and TDP-43, FUS toxicity was not buffered by wild-type Hsp104 or by any of the aspartate or glutamate phosphomimetic variants in the NTD, NBD1 or NBD2 (Fig. 3A) . However, Hsp104 T499D and Hsp104 S535D strongly mitigated FUS toxicity and were just as effective as Hsp104 A503V (Fig. 3A) .
These potentiated variants also mildly reduced FUS protein levels and this effect was most pronounced for Hsp104 A503V (Fig. 3B ). Hsp104 T499E and Hsp104 S535E also strongly rescued FUS toxicity (data not shown). In contrast, Hsp104 T499A , Hsp104 T499I , Hsp104 T499V and Hsp104 S535A did not rescue FUS toxicity ( Fig. 3C and D; data not shown) (Jackrel et al. 2014a) . Thus, rescue of FUS toxicity was enabled by phosphomimetic mutations at T499 or S535, whereas other substitutions at T499 or S535 explored here were ineffective. Hsp104 T499D and Hsp104 S535D also reduced cytoplasmic FUS aggregation in yeast ( Fig. 3E and F) . Indeed, over 80% of cells harbor cytoplasmic FUS aggregates in the vector and Hsp104 controls, whereas ∼55% and ∼40% of cells had no cytoplasmic FUS aggregates in cells expressing Hsp104 T499D and Hsp104 S535D respectively (Fig. 3F) . (Fig. 4) (Jackrel and Shorter 2014a,b; Jackrel et al. 2014a) . This toxicity at 37
• C likely reflects off-target effects such as promiscuous binding and unfolding of essential proteins (Schirmer et al. 2004; Jackrel and Shorter 2014a,b; Jackrel et al. 2014a) . Thus, we assessed whether Hsp104 T499D , Hsp104 T499E , Hsp104 S535D or Hsp104 S535E might also confer this phenotype. None of the variants were toxic at 30
• C (Fig. 4) . In contrast, expression of Hsp104 T499D or Hsp104 T499E was toxic at 37
• C, indicating that these variants have off-target effects (Fig. 4) . Hsp104 T499D and Hsp104 T499E toxicity at 37
• C was similar to Hsp104 A503V (Fig. 4) . Despite these off-target effects in the absence of disease protein, Hsp104 T499D and Hsp104 T499E potently rescue α-syn, TDP-43, and FUS toxicity. In contrast, Hsp104
S535D
and Hsp104 S535E were not toxic to yeast at 37
• C and resembled wild-type Hsp104 (Fig. 4) . Thus, Hsp104 S535D and Hsp104 S535E exhibit potentiated activity but minimal off-target toxicity, which are attractive features for therapeutic protein disaggregases to be advanced to preclinical studies.
Location of T499 and S535 in Hsp104 hexamers
Next, we mapped the potentiating phosphomimetic mutations onto the structure of Hsp104 hexamers bound to ADP ( Gates et al. 2017) . T499 is a poorly conserved residue and is typically a leucine or a large aromatic residue in other homologues (Fig. 5A ). T499 is found at the start of helix L3 in the MD and is anticipated to be readily accessible to kinases and phosphatases ( Fig. 5B ) (Yokom et al. 2016; Gates et al. 2017) . Generative REgularized ModeLs of proteINs (GREMLIN) analysis of Hsp104 suggest that T499 interacts and coevolves with A503 in helix L3 (Fig. 5C ) (Ovchinnikov, Kamisetty and Baker 2014) . Indeed, the structure of Hsp104 hexamers in the presence of ADP suggests that T499 interacts with A503 in the same protomer via a backbone hydrogen bond (Fig. 5C ) (Gates et al. 2017) . Mutation of A503 to any amino acid except proline potentiates Hsp104 (Jackrel et al. 2014a) , which may be due to disruption of the interaction with residue T499. Likewise, mutation of T499 to aspartate or glutamate, but not alanine, valine, or isoleucine likely also perturbs the interaction with A503 leading to potentiated activity. T499 may also make an intramolecular contact with E494 in helix L2 of the MD in protomer 4 (Gates et al. 2017) . Interestingly, T499 also contacts MD residues V426 and K429 in the neighboring protomer (Fig. 5C ). Mutations at V426 can also potentiate Hsp104 activity (Jackrel et al. 2014a . Thus, remodeling this network of interactions within the MD and between MDs in adjacent protomers likely yields potentiated activity. Like T499, S535 is a poorly conserved residue and is typically proline or arginine in other homologues (Fig. 5A ). S535 resides in the linker between helix L4 in the MD and the C-terminal remainder of NBD1 and is likely accessible to kinases and phosphatases (Fig. 5B) (Yokom et al. 2016; Gates et al. 2017) . Intriguingly, S535 makes intraprotomer contacts with E469 in helix L2 of the MD (Fig. 5D) (Gates et al. 2017) . S535D and E469D potentiate Hsp104 activity perhaps due to alteration of this intraprotomer MD contact .
Hsp104
T499E and Hsp104 S535E exhibit enhanced ATPase and protein-disaggregase activity Next, we purified Hsp104 T499E and Hsp104 S535E and assessed how their biochemical activity compared to Hsp104. First, we established that these phosphomimetic MD variants display elevated ATPase activity (Fig. 6A) . Hsp104 T499E exhibited ATPase activity ∼4-fold higher than Hsp104, whereas Hsp104 S535E was ∼2-fold higher (Fig. 6A ). Second, we tested the protein disaggregation and reactivation activity of Hsp104 T499E and Hsp104 S535E variants using denatured luciferase aggregates as a model substrate (Glover and Lindquist 1998) . While Hsp104 requires Hsp70 and Hsp40 for luciferase reactivation (Glover and Lindquist 1998) , Hsp104 T499E and Hsp104 S535E do not (Fig. 6B ). In the absence of Hsp70 and Hsp40, Hsp104 S535E was slightly less active than Hsp104 with Hsp70 and Hsp40, whereas Hsp104 T499E was ∼6-fold more active (Fig. 6B ). The addition of Hsp70 and Hsp40 to Hsp104 S535E variants increased luciferase reactivation by ∼6-fold, whereas Hsp104 T499E was stimulated only slightly further (Fig. 6B ). Hsp104 T499E is almost fully active without Hsp70 and Hsp40 (Fig. 6B) . In contrast, Hsp104 S535E was greatly stimulated by Hsp70 and Hsp40 (Fig. 6B ). These observations indicate differences in the mechanism of potentiation by T499E and S535E, which likely reflects the rearrangement of different structural contacts ( Fig. 5C and D) . Nonetheless, the potentiating T499E and S535E mutations increase disaggregase activity in the absence or presence of Hsp70 and Hsp40.
DISCUSSION
The subtle nature of some potentiating mutations in Hsp104 led us to hypothesize that post-translational modifications of Hsp104 at specific positions in the MD might also potentiate activity. Indeed, several serine and threonine residues throughout Hsp104 can be phosphorylated in vivo (Albuquerque et al. 2008; Holt et al. 2009; Swaney et al. 2013) . Here, we have introduced phosphomimetic aspartate or glutamate residues at these positions and assessed Hsp104 activity. Phosphomimetic mutations at T87 and S155 in the NTD, S206 and S306 in NBD1, or S577, S578 and S768 in NBD2 did not enhance Hsp104 activity. Remarkably, phosphomimetic mutations at two positions in the MD, T499 and S535, enabled Hsp104 to rescue TDP-43, FUS, and α-syn aggregation and toxicity in yeast. Moreover, Hsp104 T499E and Hsp104 S535E exhibit enhanced ATPase activity and proteindisaggregase activity in vitro. We suggest that phosphorylation of T499 or S535 may enable enhanced Hsp104 disaggregase activity in a reversible and regulated manner. Thus, enhanced disaggregase activity could be unleashed and restrained at specific locations or in response to specific environmental cues in vivo. Understanding this regulation could also inform strategies to engineer transient bursts of enhanced disaggregase activity in therapeutic settings. How do the T499D/E and S535D/E mutations potentiate Hsp104? Mutation to a negatively charged residue is important as alanine, valine or isoleucine at T499 do not enhance activity. Likewise, alanine at S535 does not potentiate Hsp104. Thus, T499 and S535 are not like A503, where any amino acid aside from alanine or proline elicits elevated disaggregase activity. Interestingly, T499 lies in helix L3 of the MD and has coevolved and interacts with A503. Mutation of T499 to aspartate or glutamate likely alters interactions with A503 in the same protomer, but also with E494 in helix L2 of the same protomer (in protomer 4) and V426 in helix L1 of the MD in the adjacent protomer (Gates et al. 2017) . Remodeling these interactions by T499D/E yields a potentiated Hsp104 variant with highly elevated disaggregase activity even in the absence of Hsp70. However, Hsp104
T499D/E also exhibits off-target toxicity, which is disadvantageous for further development as a therapeutic disaggregase. In contrast, (Gates et al. 2017) showing the positions of T499 and A503 in helix L3 of the MD of protomer 3 and V426 and K229 in helix L1 of protomer 4. The GREMLIN score for the interaction between T499 and A503 is indicated. (D) View of protomer 3 of Hsp104 bound to ADP (Gates et al. 2017) showing the positions of S535 in the linker between helix L4 of the MD and NDB1 and E469 in helix L2 of the MD of the same protomer.
Hsp104
S535D/E is not toxic. Hsp104 S535E disaggregase activity is not as elevated as Hsp104 T499E in the absence or presence of Hsp70, but is substantially higher than Hsp104. S535D/E likely disrupts an intraprotomer interaction with E469 in helix L2 of the MD. Hsp104 E469D is also an enhanced Hsp104 variant, which like Hsp104 S535D/E exhibits reduced off-target toxicity . Thus, Hsp104 S535D/E and Hsp104 E469D are interesting variants to advance in preclinical studies as they potently rescue proteotoxicity with minimal side effects. Under what conditions are T499 and S535 phosphorylated in vivo? One study found that Hsp104 may be phosphorylated at T499 and S535 under conditions of DNA damage stress (Albuquerque et al. 2008) . These observations raise the possibility that Hsp104 might get phosphorylated at T499 or S535 as part of a stress response to elicit enhanced disaggregase activity, which is cytoprotective. Once the stress has passed, dephosphorylation of T499 or S535 would restore Hsp104 activity to basal levels. In this way, yeast may utilize phosphorylation of T499 or S535 to unleash enhanced Hsp104 disaggregase activity exactly when or where it is needed in a reversible and regulated manner.
Curiously, T499 and S535 are not very well conserved residues. Indeed, of the 4950 Hsp104 species variants assessed in our GREMLIN analysis, ∼1.7% had T at position 499. Indeed, L, Y or F were most commonly found at position 499 (Fig. 5A) . Likewise, only ∼13% of Hsp104 species variants had S at position 535 (Fig. 5A) . At this position, P or R was the most commonly found residue. Thus, this potential method of Hsp104 regulation via phosphorylation of T499 or S535 may be idiosyncratic to a restricted number of species. However, position 499 is frequently tyrosine in ∼16% of species, and thus could be regulated in a similar manner via tyrosine phosphorylation. Further studies are needed to reveal under what exact conditions Hsp104 is phosphorylated at T499 or S535 in yeast. The identity of Hsp104 kinases and phosphatases also needs to be delineated. Indeed, it will be of great interest to reconstitute the regulation of potentiated Hsp104 disaggregase activity in vitro via the addition of defined kinases and phosphatases. Other post-translational modifications may also unleash enhanced Hsp104 activity in a regulated manner. For example, the MD of Hsp104 can be modified via ubiquitylation, succinylation, and acetylation, which might also profoundly activate Hsp104 (Henriksen et al. 2012; Swaney et al. 2013; Weinert et al. 2013) .
Understanding exactly how potentiated Hsp104 activity may be elicited and silenced by post-translational modifications might also help inform therapeutic strategies based on introduction of exogenous Hsp104 into degenerating neurons (Vacher, Garcia-Oroz and Rubinsztein 2005; Perrin et al. 2007; Lo Bianco et al. 2008; Vashist, Cushman and Shorter 2010; Cushman-Nick, Bonini and Shorter 2013) . For example, it would likely be beneficial to reduce expression or activity of a therapeutic disaggregase after it has remediated the deleterious misfolding driving neurodegeneration. In this way, any toxic side effects of the disaggregase that might occur after misfolding is corrected could be avoided (Mack and Shorter 2016; Shorter 2016; Jackrel and Shorter 2017; Shorter 2017; Yasuda et al. 2017) . A potential method to achieve this goal of tunable activity would be to synchronize the activity of the disaggregase based on the level of stress-signaling output of degenerating neurons. For example, Cdk5, a predominantly neural kinase exhibits hyperactive activity in degenerating neurons in various disorders (Su and Tsai 2011; Cheung and Ip 2012) . Engineering Hsp104 with a Cdk5 consensus site at T499 or S535 could enable enhanced disaggregase activity elicited by phosphorylation by Cdk5, which would then decline upon restoration of proteostasis, mitigation of degeneration, and return of Cdk5 activity to normal levels. Variations on this theme that involve kinases other than Cdk5 or other reversible post-translational modifications can also be readily envisioned. In this way, enhanced disaggregase activity could be tuned via post-translational modification to suit the exact needs of the neuron.
We close with an important caveat. The phosphomimetic mutations in Hsp104 studied here may not accurately mimic phosphorylation of T499 or S535. In many cases, phosphomimetic mutations accurately phenocopy serine and threonine phosphorylation events and have been extremely informative (Lowe et al. 1998; Buck et al. 1999; Vitari et al. 2005; McKay and Morrison 2007; Truman et al. 2012; Dephoure et al. 2013) . Indeed, phosphorylation sites often evolve from ancestral aspartate or glutamate residues (Pearlman, Serber and Ferrell 2011) . However, in some cases, phosphomimetic mutations have not accurately represented the effects of phosphoserine or phosphothreonine (Dirac-Svejstrup et al. 2000; Paleologou et al. 2010; Hart and Vogt 2011; Dephoure et al. 2013; Skinner et al. 2017) . Indeed, the size of the ionic shell and the negative charge of the phosphate group are different than aspartate or glutamate (Hunter 2012 ). Thus, phosphoserine or phosphothreonine creates a distinctive chemical microenvironment that is imperfectly mimicked by aspartate or glutamate (Hunter 2012) . Consequently, it will be important to determine the activity of Hsp104 with phosphothreonine at position 499 or phosphoserine at position 535. Advances in technology to selectively incorporate non-natural amino acids, such as phosphoserine and phosphothreonine, into proteins are now available, which will enable general methods to biosynthesize defined phosphorylated versions of Hsp104 and indeed any specific phosphoprotein (Rogerson et al. 2015; Zhang et al. 2017) .
